Eczema Hospital Treatments 
First Derm
MARCH 22, 2024
Eczema herpeticum Medically reviewed by The Dermatologists and written by Dr. Alexander Börve In A Nutshell What It Is : Skin infection marked by fever and clusters of itchy blisters, often complicating atopic dermatitis. What is Eczema Herpeticum? What is Eczema Herpeticum? Also known as Kaposi varicelliform eruption.
The Dermatology Digest
JANUARY 14, 2025
TSW commonly described as extremely red and painful skin arising when cortisone cream treatment is tapered or stopped. The new study targeted adults with atopic eczema, a group that often uses cortisone cream, who also identified as having TSW. A majority of the participants described concurrent symptoms of both atopic eczema and TSW.
The Dermatology Digest
APRIL 9, 2024
. “We need more images of patients as visual aids in communication,” says study author Sam Polesie, MD, PhD, Associate Professor at the Sahlgrenska Academy at the University of Gothenburg and a dermatologist at Sahlgrenska University Hospital in Sweden, in a news release. “It
US Dermatologt Partners
NOVEMBER 20, 2024
The team will treat various dermatologic conditions such as acne, eczema, rosacea and skin cancer. Louis University Hospital, and completed a residency in dermatology at the University of Oklahoma College of Medicine, serving as chief resident in his final year. This year alone, U.S. “By For now, the clinic is open from 8 a.m.
The Dermatology Digest
JANUARY 30, 2024
Five investigators have received funding through the 2023 PeDRA Research Grants, Career Bridge Research Grant, Pediatric Alopecia Areata Challenge Grant, and Childhood Eczema Challenge Grant programs. The post And the Winners Are…PeDRA Announces 2023 Grant Recipients appeared first on The Dermatology Digest.
The Dermatology Digest
MARCH 13, 2024
Adam Friedman, MD, Professor and Chair of Dermatology at George Washington School of Medicine and Health Sciences in Washington, DC, shares his excitement about chronic spontaneous urticaria (CSU) treatments coming down the pike including remibrutinib, Novartis’ investigational oral Bruton’s tyrosine kinase inhibitor.
The Dermatology Digest
MARCH 12, 2024
Eichenfield is Chief of Pediatric and Adolescent Dermatology at Rady Children’s Hospital–San Diego, Vice Chair of the Department of Dermatology, and Professor of Dermatology and Pediatrics at the University of California, San Diego (UCSD) School of Medicine. Here’s what he had to say: What is the main takeaway of this study?
Expert insights. Personalized for you.
52 
Let's personalize your content